GC
MDGL icon

Guggenheim Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Guggenheim Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
2,399
-470
-16% -$241K 0.01% 908
2026
Q1 		$1.5M Buy
2,869
+708
+33% +$338K 0.01% 814
2025
Q4 		$1.26M Buy
2,161
+536
+33% +$274K 0.01% 829
2025
Q3 		$745K Sell
1,625
-413
-20% -$154K 0.01% 1026
2025
Q2 		$617K Sell
2,038
-164
-7% -$48.9K ﹤0.01% 1076
2025
Q1 		$729K Sell
2,202
-466
-17% -$153K 0.01% 1025
2024
Q4 		$823K Sell
2,668
-978
-27% -$275K 0.01% 1002
2024
Q3 		$774K Buy
3,646
+311
+9% +$79.6K 0.01% 1219
2024
Q2 		$934K Buy
3,335
+365
+12% +$86.9K 0.01% 1156
2024
Q1 		$793K Sell
2,970
-451
-13% -$106K 0.01% 1289
2023
Q4 		$792K Buy
3,421
+284
+9% +$49.7K 0.01% 1266
2023
Q3 		$458K Buy
3,137
+431
+16% +$81.1K ﹤0.01% 1468
2023
Q2 		$625K Sell
2,706
-431
-14% -$117K ﹤0.01% 1360
2023
Q1 		$760K Buy
+3,137
New +$855K 0.01% 1305
2019
Q4 		– Sell
-16,064
Closed -$1.39M – 2119
2019
Q3 		$1.39M Sell
16,064
-1,043
-6% -$97.9K 0.01% 1167
2019
Q2 		$1.79M Buy
17,107
+926
+6% +$99.2K 0.01% 1104
2019
Q1 		$2.03M Sell
16,181
-1,622
-9% -$202K 0.02% 1065
2018
Q4 		$2.01M Buy
+17,803
New +$2.76M 0.02% 1039
2015
Q3 		– Sell
-341
Closed -$27K – 3011
2015
Q2 		$27K Buy
+341
New +$28.6K ﹤0.01% 2986

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Guggenheim Capital's MDGL Position: Q2 2026 in Review

Guggenheim Capital reduced its Madrigal Pharmaceuticals (MDGL) stake by 16% in Q2 2026, selling an estimated $241K and leaving 2,399 shares worth $1.29M. The position accounts for 0.01% of the portfolio, ranked #908.

Guggenheim Capital first reported a position in MDGL in Q2 2015 and has held it in 19 quarters since. The position peaked at $2.03M in Q1 2019. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Guggenheim Capital held 2,399 shares of Madrigal Pharmaceuticals worth $1.29M as of Q2 2026.
  • Guggenheim Capital sold 470 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $241K.
  • Madrigal Pharmaceuticals made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #908 holding.
  • Guggenheim Capital first reported a position in Madrigal Pharmaceuticals in Q2 2015 and has held it in 19 quarters since.
  • Guggenheim Capital's Madrigal Pharmaceuticals position peaked at $2.03M in Q1 2019.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.